Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 3/20 | 0.67 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.67 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7117727 | 1.00 | PDGFRB (0.67) | PDGFRBPDGFRARAB9AKDM4EKMT2A | |
| SCHEMBL563572 | 0.84 | PDGFRB (0.73) | PDGFRBPDGFRARAB9AKDM4EKMT2A | |
| SCHEMBL563573 | 0.84 | PDGFRB (0.73) | PDGFRBPDGFRARAB9AKDM4EKMT2A | |
| SCHEMBL372028 | 0.83 | PDGFRB (0.67) | PDGFRBPDGFRARAB9AKDM4EKMT2A | |
| SCHEMBL6850815 | 0.83 | PDGFRB (0.67) | PDGFRBPDGFRARAB9AKDM4EKMT2A | |
| SCHEMBL372262 | 0.83 | PDGFRB (0.67) | PDGFRBPDGFRARAB9AKDM4EKMT2A | |
| SCHEMBL3906668 | 0.83 | PDGFRB (0.67) | PDGFRBPDGFRARAB9AKDM4EKMT2A | |
| SCHEMBL10162435 | 0.83 | PDGFRB (0.67) | PDGFRBPDGFRARAB9AKDM4EKMT2A | |
| SCHEMBL3906662 | 0.83 | PDGFRB (0.67) | PDGFRBPDGFRARAB9AKDM4EKMT2A | |
| SCHEMBL2056162 | 0.83 | PDGFRB (0.67) | PDGFRBPDGFRARAB9AKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0984975-B1 | MULTICYCLIC ERYTHROMYCIN DERIVATIVES | ABBOTT LAB (US) | 2003-04-23 | — | — | EP | claimed |
| JP-2002500669-A | — | — | 2002-01-08 | — | — | JP | claimed |
| EP-0984975-A1 | MULTICYCLIC ERYTHROMYCIN DERIVATIVES | Abbott Laboratories (US) | 2000-03-15 | — | — | EP | claimed |
| US-5922683-A | ANTIBIOTICS TREATING BACTERIAL INFECTION | ABBOTT LABORATORIES (US) | 1999-07-13 | — | — | US | claimed |
| WO-1998054197-A1 | MULTICYCLIC ERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1998-12-03 | — | — | WO | claimed |
| US-7332476-B2 | Pyridyl substituted ketolide antibiotics | NOVARTIS AG (CH) | 2008-02-19 | — | — | US | disclosed |
| US-20050009764-A1 | Pyridyl substituted ketolide antibiotics | CHIRON CORPORATION (US) | 2005-01-13 | — | — | US | disclosed |
| US-6756359-B2 | ADMINISTERING A 14 MEMBERED MACROLIDE AND KETOLIDE ANTIBIOTICS CONTAINING C12 MODIFICATIONS TO A PATIENT SUFFERING FROM BACTERIAL INFECTIONS | CHIRON CORPORATION | 2004-06-29 | — | — | US | disclosed |
| US-20030125266-A1 | C12 Modified erythromycin macrolides and ketolides having antibacterial activity | CHU DANIEL (US) | 2003-07-03 | — | — | US | disclosed |
| EP-0984975-B1 | MULTICYCLIC ERYTHROMYCIN DERIVATIVES | ABBOTT LAB (US) | 2003-04-23 | — | — | EP | disclosed |
| EP-0984975-A1 | MULTICYCLIC ERYTHROMYCIN DERIVATIVES | Abbott Laboratories (US) | 2000-03-15 | — | — | EP | disclosed |
| US-5922683-A | ANTIBIOTICS TREATING BACTERIAL INFECTION | ABBOTT LABORATORIES (US) | 1999-07-13 | — | — | US | disclosed |
| WO-1998054197-A1 | MULTICYCLIC ERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009764-A1 | Pyridyl substituted ketolide antibiotics | PKLR, KHK, PGD | PDGFRB 2398/4885PDGFRA 2996/4885RAB9A 1736/4885 |
| US-20030125266-A1 | C12 Modified erythromycin macrolides and ketolides having antibacterial activity | MRPL21, CYP51A1, CEL | PDGFRB 4681/4885PDGFRA 4701/4885RAB9A 1155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.